Could Epizyme Inc. (NASDAQ:EPZM) bite your fingers?


Epizyme Inc. (NASDAQ:EPZM), whose market capitalization now stands at $886.82M, reported EPS of $-2.07 in the last financial year. That indicates the stock has price-to-earnings ratio of – at the prevailing stock price. This fiscal year’s EPS is projected to grow 41.90% over the preceding year.

For the forward P/E metric, market analysts have a 12-month target price of $24.38 on the stock of Epizyme, Inc..

Over the preceding five years, Epizyme, Inc. has recorded EPS improvement of 33.30%. That against sales growth of 2.90% over the same 5-year period.

Let’s look into the charts of the stock

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

Epizyme, Inc. also recorded return assets of -45.40%, return on of -55.40% and return on investments of -55.30%.

Analysts are projecting the stock of Epizyme, Inc. to be trading at $24.38 in the next 12-months, but what been its performance quality until now?

The stock jumped/declined 26.64% in the previous week, and for the preceding month it is up/down -10.22%. For the quarter and for the fiscal year so far, the shares have risen/decline -14.45% and 19.83%, respectively. From a year earlier, the stock has moved 22.36%.

What about the volatility of the equity? First, the stock?s beta is 2.38. Investors would do well to note that beta of less than 1 indicates that the underlying security is less volatile as against the market, but beta over one implies that a security is extremely volatile compared to market.

In terms of monthly or weekly volatility, Epizyme, Inc. has a weekly volatility of 18.80% and monthly volatility of 10.72%.

Epizyme, Inc. EPZM announced positive interim data from an ongoing phase II study evaluating pipeline candidate tazemetostat, an oral EZH2 inhibitor, as a monotherapy in patients with relapsed or refractory follicular lymphoma (r/rFL) or diffuse large B-cell lymphoma (DLBCL) based on their EZH2 mutational status. The data were presented at the International Conference on Malignant Lymphoma (ICML).

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.